REH/RFP stable cell line

REH/RFP cells are derived from the human B-cell acute lymphoblastic leukemia (ALL) cell line REH by stably integration of a constitutive RFP stably expression construct. REH cells are used to study the biology of B-ALL, including signaling pathways, cell proliferation, and apoptosis, as well as test new therapeutic approaches. REH cells can be used to identify suitable antigen targets for CAR-T therapies. Common targets for B-cell malignancies include CD19 and CD22, both of which are expressed on REH cells. REH/RFP cells stably express RFP, can be used for in vitro assays and in vivo imaging.